Aller au contenu principal
  • Partenaires agréés
  • À propos d'ELGA
    • À propos d'ELGA
    • Carrières
    • Événements
  • Assistance
    • Aménagement du laboratoire
    • Enregistrer un produit
    • Register Your Product (USA & Canada Only)
  • Contact
  • U.S.A.
  • U.K.
  • Deutschland
  • España
  • Italia
  • Brasil
  • 日本
  • 中国
Accueil ELGA LabWater
  • Produits
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • Gamme complète des produits ELGA
  • Applications
    • Analyse microbiologique
    • Biochimie clinique
    • Chromatographie en phase gazeuse
    • Chromatographie en phase liquide
    • Cultures cellulaires
    • Exigences générales d'un laboratoire en matière d'eau
    • Génétique
    • Immunochimie
    • Spectrométrie de masse
    • Spectrophotométrie
    • Spectroscopie atomique
    • Électrochimie
  • Technologies
    • Charbon actif
    • Filtration
    • Osmose inverse
    • PureSure
    • Ultraviolet
    • Échange ionique
    • Électrodéionisation (EDI)
  • Impuretés dans l'eau
    • Composés inorganiques
    • Composés organiques
    • Gaz dissous
    • Micro-organismes et bactéries
    • Particules
  • Knowledge
    • Blog
    • Études de cas
    • Eau ultra-pure
    • Guides et livres blancs
  • Produits
    • PURELAB
    • CENTRA
    • MEDICA
      • Hubgrade
      • MEDICA BIOX
    • BIOPURE
    • Gamme complète des produits ELGA
      • PURELAB® Classic
  • Applications
    • Analyse microbiologique
    • Biochimie clinique
    • Chromatographie en phase gazeuse
    • Chromatographie en phase liquide
      • Hochleistungsflüssigkeitschromatographie (HPLC)
    • Cultures cellulaires
    • Exigences générales d'un laboratoire en matière d'eau
    • Génétique
    • Immunochimie
    • Spectrométrie de masse
    • Spectrophotométrie
    • Spectroscopie atomique
    • Électrochimie
  • Technologies
    • Charbon actif
    • Filtration
    • Osmose inverse
    • PureSure
    • Ultraviolet
    • Échange ionique
    • Électrodéionisation (EDI)
  • Impuretés dans l'eau
    • Composés inorganiques
    • Composés organiques
    • Gaz dissous
    • Micro-organismes et bactéries
    • Particules
  • Knowledge
    • Blog
      • Analytical Chemistry
      • Clinical & Pharma
      • Cool Science
      • Environment and sustainability
      • Life in the lab
      • Purelab product design
      • Science of the future
      • Water Purity
      • Water in the lab
    • Études de cas
      • Abbott Diagnostics opte pour les systèmes ELGA MEDICA en Asie du Sud
      • Beam Me Up, Scotty: PURELAB® Option Q Delivers Essential Ultra Pure Water
      • Argenta chooses DKSH New Zealand to deliver Ultrapure water in Animal Pharma
      • Clean Water for a Clean Future
      • LS Scientific & ELGA deliver UltraPure water to the NAFDAC Laboratory
      • Lifebrain Group chooses ELGA as water partner for new modern 24/7 PCR-COVID-19 laboratory in Vienna, Austria.
      • Critital Tests Benefit from PURELAB® Option Reliable Pure Water
      • DASA : la plus grande société de diagnostic médical au Brésil
      • ELGA aide les laboratoires d'immuno-sérologie à maximiser la disponibilité
      • Fondazione Telethon Continues to Choose ELGA Labwater as a Trusted Partner
      • Importance de l'eau ultra-pure de type 1+ pour la mise au point de médicaments génériques
      • MEDICA® Pro sélectionné pour les analyseurs Siemens ADVIA® à l'hôpital général de la ville
      • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
      • PURELAB® Option R Guarantees Pure Water for Leading Microfluidics Technology
      • PURELAB® Pulse Delivers Reliable Water Quality and Quantity for a Wide Range of Applications
      • PURELAB® flex : un système de formation idéal pour la méthode de recherche actuelle
      • Powering Cutting-Edge Gene Research
      • Sichere Reinstwasserversorgung für präzise Produkttests
      • Zentrale Reinstwasser-Aufbereitung für Analyser
      • ELGA LabWater and Beckman Coulter Join Forces
      • Applied New Technologies Department Improves ICP, IC & HPLC Sample Turnaround Times with PURELAB®
      • Découvrir les secrets de l'Antarctique à l'aide d'eau ultra-pure
      • Advancing Genetic Technologies
      • Cross Infection Control: Pure and Simple
      • Researching effective new ways to prevent cardiovascular disease at the University of Columbia
    • Eau ultra-pure
    • Guides et livres blancs
      • Pureté de l'eau pour la HPLC
      • HPLC dans le secteur pharmaceutique
      • Réduire les risques cliniques
      • Durabilité
  • U.S.A.
  • U.K.
  • Deutschland
  • España
  • Italia
  • Brasil
  • 日本
  • 中国
  • Politique relative à la confidentialité
  • Conditions générales
  • Conformité juridique mondiale
  • Brevets
  • Impressum
  • Accueil
  • Could Faecal Testing Help Personalise Cancer Treatment?
Analytical Chemistry
Water Purity

Could Faecal Testing Help Personalise Cancer Treatment?

22 juin 2020
- by Dr Alison Halliday

Scientific Testing

A new study suggests that measuring short-chain fatty acids in the gut may offer a way to predict which cancer patients will benefit from immunotherapy.


Cancer therapies that target elements of the immune system – immunotherapies – are showing remarkable results for many patients. So-called ‘immune checkpoint inhibitors’ work by interfering with the mechanism that cancer cells use to evade destruction by the body’s immune system. Examples include nivolumab and pembrolizumab, which target a molecule on the surface of cells called PD–1.

Treating patients with immune checkpoint inhibitors can shrink tumours and improve survival rates, even for whom other therapies have failed. However, the response to these drugs varies widely from person to person – particularly for those with solid tumours.

If clinicians could predict who will benefit from cancer immunotherapies in advance, this would help spare many patients from the risk of unnecessary side effects. Defining the factors that can influence this variability in response will also improve our understanding of how these treatments work, identifying new opportunities for widening their effectiveness in the future.

The Gut Microbiome is a Suspect

Several studies have suggested that the population of microorganisms in our gut may influence the success of cancer immunotherapies. But the mechanisms behind this potential association remain unclear. One suspect are the short-chain fatty acids, which are the major end–products of gut microbiome–mediated metabolism. These molecules are thought to have wide-ranging effects on the whole body – including in modulating the immune response. 

In a new study, published in JAMA Network Open, scientists set out to explore whether short-chain fatty acids are associated with the clinical outcomes of patients with solid tumours treated with nivolumab or pembrolizumab.1

Evaluating Short-Chain Fatty Acid Concentrations

The researchers recruited 52 patients with solid tumours before they started treatment with nivolumab or pembrolizumab. They collected faecal and plasma samples and measured the concentrations of various short-chain fatty acids using ultra–high–performance liquid chromatography coupled with tandem mass spectrometry.

For these experiments, they used ultrapure water from an ELGA PURELAB® flex 5 water purification system, minimising the risk of introducing contaminants that may affect their results.

The scientists carried out scans to measure the size of the patients’ tumours at regular intervals over the study. They then carried out statistical analyses to evaluate if the levels of short-chain fatty acids were related to their response to treatment. They found that high concentrations of acetic acid, propionic acid, butyric acid and valeric acid in faecal samples – and isovaleric acid in plasma – were associated with patients living longer without their disease getting any worse. 

A Non–Invasive Test

This is the first study to identify a link between short-chain fatty acids and the effectiveness of PD–1 treatment for solid cancers. 

If these results are confirmed in larger studies, testing faecal samples from patients with solid tumours could offer a relatively simple way to predict who may benefit from nivolumab or pembrolizumab– paving the way to a more personalised approach to cancer immunotherapy in the future.

Why Choose ELGA LabWater?

ELGA’s expert engineers, chemists and scientists are at the forefront of technological innovation. We continue to introduce game-changing features to the laboratory water market.
 

Reference:

  1. Nomura M, et al. Association of Short–Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment with Nivolumab or Pembrolizumab in Patients with Solid Cancer Tumors. JAMA Network Open 2020;3(4):e202895


Dr Alison Halliday

After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

risk whitepaper

When lives are at stake, there is no margin for error. Your clinical analyser must receive a constant and reliable supply of CLRW. 

Find out how to protect your test results

                   Click Here

 

  • Enquiry
  • Obtenir un devis
  • Réservez une démo
  • Trouver un partenaire approuvé

Enquiry

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Obtenir un devis

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Réservez une démo

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater US Headquarters

Lane End Business Park
Lane End, High Wycombe
HP14
3BY Royaume-Uni
T : +44 (0) 203 567 7300 - Fax
 : +44 (0) 203 567 7205

Siège social ELGA LabWater

Lane End Business Park
Lane End, High Wycombe
HP14
3BY Royaume-Uni
T : +44 (0) 203 567 7300 - Fax
 : +44 (0) 203 567 7205

Études de cas

  • Diagnostics Abbott
  • Diagnostics médicaux DASA
  • Institut médical NeoDIN
  • Fondation North Staffordshire NHS Trust
  • Lycée professionnel d'Olsberg

Ressources

  • En savoir plus sur l'eau ultra-pure
  • Guides et livres blancs
  • Technologies de purification
  • Applications
  • Impuretés dans l'eau

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • Langue
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Autres sites Veolia
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies

© VWS (UK) Ltd. exerçant sous le nom ELGA LabWater.2023-Tous les droits sont réservés.
ELGA est la marque mondiale d'eau de laboratoire de Veolia.

  • Politique relative à la confidentialité
  • Conditions générales
  • Conformité juridique mondiale
  • Brevets
  • Impressum
Elga Veolia
TOP

© 2017 ELGA Veolia